[Therapeutic targets in polyglutamine diseases].
Hori
Seiji
S
shori@lif.kyoto-u.ac.jp
Kakizuka
Akira
A
D000251:Adenosine Triphosphatases; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016227:Benzoquinones; D018797:Cell Cycle Proteins / Q000502:physiology; D003224:Congo Red / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015195:Drug Design; D004721:Endoplasmic Reticulum / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D047029:Lactams, Macrocyclic; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000235:genetics*; D010455:Peptides / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D011809:Quinones / Q000627:therapeutic use; D034622:RNA Interference; D000074405:Valosin Containing Protein; D000077337:Vorinostat
D000970:Antineoplastic Agents; D016227:Benzoquinones; D018797:Cell Cycle Proteins; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D047029:Lactams, Macrocyclic; D010455:Peptides; D011809:Quinones; C097188:polyglutamine; D003224:Congo Red; D000077337:Vorinostat; D000251:Adenosine Triphosphatases; D000074405:Valosin Containing Protein; C001277:geldanamycin